KTRA

Kintara Therapeutics Stock Price

1.48
-0.02 (-1.33%)
Upgrade to Real-Time
Afterhours (Closed)
1.48
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Kintara Therapeutics Inc KTRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -1.33% 1.48 00:00:10
Close Price Low Price High Price Open Price Previous Close
1.51 1.43 1.55 1.46 1.50
Bid Price Ask Price Spread News
1.42 1.75 0.33 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,150 314,718 $ 1.53 $ 480,312 450,964 1.00 - 1.95
Last Trade Time Type Quantity Stock Price Currency
19:57:43 formt 200 $ 1.48 USD

Kintara Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 34.84M 23.54M 23.15M $ - $ - -0.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 377.82k 7.70%

more financials information »

Kintara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KTRA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.501.601.431.50158,005-0.02-1.33%
1 Month1.331.831.31051.57338,1290.1511.28%
3 Months1.211.951.001.50474,0160.2722.31%
6 Months1.211.951.001.50474,0160.2722.31%
1 Year1.211.951.001.50474,0160.2722.31%
3 Years1.211.951.001.50474,0160.2722.31%
5 Years1.211.951.001.50474,0160.2722.31%

Kintara Therapeutics Description

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.


Your Recent History
NASDAQ
KTRA
Kintara Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.